India HbA1c Market

Increased prevalence of thalassemia and sickle cell among India

HbA1c testing is a crucial tool for type 2 diabetes patients to monitor their blood sugar control and manage their condition effectively. Regular HbA1c monitoring assists physicians and patients to assess diabetes management, adjust treatment as needed, and reduce the risk of complications. India is often referred to as the “Diabetes Capital of the World,” and the factors that are driving India to become a diabetes capital are India has the largest population in the world and India is undergoing rapid urbanization, leading to lifestyle changes.

Moreover, India has a high burden of thalassemia and sickle cell diseases, with a significant number of individuals affected by these conditions. According to estimates, India has the highest number of thalassemia patients in the world, with approximately 50 million carriers and over 10,000 thalassemia major patients. The increasing prevalence of these conditions in the country has led to a rising demand for HBa1c testing. Healthcare providers and laboratories are increasingly performing these tests to diagnose and monitor individuals with thalassemia and sickle cell diseases.

Thus, the demand for HbA1c testing among Indians is increasing due to rising prevalence of type 2 diabetes, thalassemia, and sickle cell disease.

The increasing prevalence of diabetes in India is a pivotal driver for the Global India HbA1c Market Industry. As of 2024, approximately 77 million people in India are estimated to be living with diabetes, a figure projected to rise significantly in the coming years. This surge in diabetes cases necessitates regular monitoring of HbA1c levels, thereby driving demand for testing and management solutions. The Global India HbA1c Market Industry is expected to witness substantial growth, with a market value of 750 USD Million in 2024, reflecting the urgent need for effective diabetes management strategies.

The increase in healthcare expenditure in India is a significant factor propelling the Global India HbA1c Market Industry. With rising disposable incomes and a growing focus on health, both public and private sectors are investing more in healthcare services. This trend is likely to facilitate better access to diagnostic services, including HbA1c testing, thereby driving market growth. As healthcare spending continues to rise, the market is projected to expand, potentially reaching 1500 USD Million by 2035, indicating a robust investment in diabetes management and healthcare infrastructure.

Government initiatives aimed at combating diabetes and promoting health awareness play a crucial role in shaping the Global India HbA1c Market Industry. Various health programs and campaigns are being implemented to educate the population about diabetes management and the importance of regular HbA1c testing. These initiatives are likely to enhance accessibility to diagnostic services and promote preventive healthcare measures. As a result, the market is expected to expand, with projections indicating a growth trajectory that could reach 1500 USD Million by 2035, driven by increased government support and public health initiatives.

The rising awareness regarding diabetes management among the Indian population is a key driver for the Global India HbA1c Market Industry. Educational campaigns and community outreach programs are increasingly informing individuals about the significance of monitoring HbA1c levels. This heightened awareness is fostering a proactive approach to health management, leading to increased demand for HbA1c testing services. As more individuals seek regular monitoring, the market is poised for growth, with expectations of reaching a market value of 750 USD Million in 2024, reflecting the changing attitudes towards diabetes care.

Technological advancements in diagnostic tools and methodologies are significantly influencing the Global India HbA1c Market Industry. Innovations such as point-of-care testing devices and mobile health applications are enhancing the efficiency and accuracy of HbA1c testing. These technologies not only facilitate timely diagnosis but also empower patients to manage their health more effectively. The integration of advanced technologies is likely to attract investments and foster market growth, contributing to an anticipated compound annual growth rate of 6.5% from 2025 to 2035, thereby reshaping the landscape of diabetes management in India.

The India HbA1c testing market is distinguished by the presence of numerous local players catering to HbA1c testing products that are evolving at a rapid pace. Furthermore, the rising prevalence of type 2 diabetes and increased prevalence of thalassemia and sickle cell among India is further driving the growth of India HbA1c testing market during the forecast period. The major players have adopted a strategy of obtaining regulatory approval from government agencies for their products and signing contracts and agreements to broaden their reach and reduce operational costs.

Furthermore, PTS Diagnostics (US) manufactures point-of-care biometric testing devices. The company offers diagnostic products and accessories to the healthcare industry through its signature products, which include the CardioChek family of lipid and glucose analyzers & products, A1CNow + systems, portable analyzers that provide a HbA1c measurement, a tobacco-detection device, and many other devices. Additionally, PTS Diagnostics offers the PTS ConnectTM solution, a turnkey population health management (PHM) platform, to urgent care centers, retail clinics, and health and wellness enterprises. Moreover, the company launched the A1CNow+ Controls for the A1CNow+ Test System.

A1CNow+ Controls can be kept at room temperature for seven days, in the refrigerator for eight months, or in the freezer for up to three years. Within minutes, both solution’s levels each in a dropper-style vial can be used. Its goal is to ensure accurate A1C measurements. Customers can buy this product from the US, EU, UK, and including India.